Table 2.
Anti-eosinophil therapeutics
| Therapeutic parameters | Mepolizumab | Reslizumab | Benralizumab | Lirentelimab (AK002) |
|---|---|---|---|---|
| Target | IL-5 | IL-5 | IL-5Rα | Siglec-8 |
| Antibody (parent) | Humanized IgG1κ (murine 2B6) | Humanized IgG4κ (rat 39D10) | Humanized nonfucosylated IgG1κ | Humanized nonfucosylated IgG1κ |
| Indicated for severe eosinophilic asthma | Yes (100 mg SC, four doses weekly) | Yes (3 mg/kg IV, four doses weekly) | Yes (30 mg SC, three doses weekly, then every eight weeks) | No |
| Indicated for EGPA/HES | Yes | Noa | Noa | No |
| Other indications being pursued | HES, EoE, CRSwNP | CRSwNP | HES, EGID, CRSwNP | EGID |
| Pediatric indication | 6 years and above | No | 12 years and above | No |
| Eosinophil reduction (blood/tissue) | Yes (↓) | Yes (↓↓) | Near complete (↓↓↓) | Near complete (↓↓↓) |
| Effect on other cells | No | No | Reduction of basophils | Inhibition of mast cells |
Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyposis; EGID, eosinophilic gastrointestinal disease; EGPA, eosinophilic granulomatosis with polyangiitis; EoE, eosinophilic esophagitis; HES, hypereosinophilic syndrome; IV, intravenous; SC, subcutaneous; Siglec-8, sialic acid–binding immunoglobulin-like lectin 8.
a
Pending studies.